Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Interview With Siddhartha Mukherjee, Author of The Emperor of All Maladies

March 4th 2011

Siddhartha Mukherjee, MD, discusses his book The Emperor of All Maladies.

Avastin Alarm

March 4th 2011

A meta-analysis of randomized controlled trials revealed treatment-related fatalities were 1.5 times higher for combination treatment with Avastin (bevacizumab) and chemotherapy versus chemotherapy alone

Afinitor Active in Pancreatic NET

March 4th 2011

In the RADIANT-3 (RAD001 In Advanced Neuroendocrine Tumors) phase III study involving patients with pancreatic neuroendocrine tumors (NET)

Canine Cancer Hounds

March 4th 2011

A black Labrador retriever was able to detect colorectal cancer >90% of the time when sniffing a patient%u2019s breath or stool sample.

Racial/Ethnic and Age Disparities in Chemotherapy Selection for Colorectal Cancer

March 3rd 2011

Studies have evaluated racial/ethnic and age disparities in whether patients receive chemotherapy for nonmetastatic colo-rectal cancer

ASCO GI Coverage: Women Who Use Bisphosphonates for Osteoporosis Reduce Their Risk of Colorectal Cancer

March 2nd 2011

The risk of colorectal cancer declined by 33% among postmenopausal women taking oral bisphosphonates for osteoporosis

ASCO GI Coverage: Australian Study Finds ISH to Be the Best Assessor of HER2 Expression in Gastric Cancer

March 2nd 2011

In situ hybridization (ISH) yields the best results for assessing HER2 expression in gastric cancer, according to a multilaboratory analysis of testing methods.

ASCO GI Coverage: Study Finds Tumor Characteristics Correlate With Survival in Stomach, Esophageal Cancers

March 2nd 2011

An analysis of the National Cancer Institute's Surveillance Epidemiology and End Results (SEER) database showed that advanced gastric or esophageal cancer confers a poor prognosis

ASCO GI Coverage: Imatinib Trough Levels Remain Stable in Most Advanced GIST Patients During Long-Term Treatment

March 2nd 2011

Patients with gastrointestinal stromal tumors (GIST) had stable plasma concentrations of imatinib during long-term treatment, reported Yoon-Koo Kang, MD, PhD, and colleagues at the Gastrointestinal Cancers Symposium.

ASCO GI Coverage: European Study Shows Bevacizumab to Be Ineffective as Adjuvant Therapy

March 2nd 2011

The results of a large, multicenter trial showed that the addition of bevacizumab to adjuvant chemotherapy failed to improve disease-free survival (DFS) compared with chemotherapy alone.

ASCO GI Interview Series: Robert Rosenberg, MD, Discusses Advantages of ColoPrint Test

March 2nd 2011

At the 2011 symposium in San Francisco, California, Oncology & Biotech News spoke with the author of one of the featured presentations at the meeting

ASCO GI Interview Series: Improving Patient Outcomes in Pancreatic Cancer: A Conversation with Mitchell C. Posner, MD

March 2nd 2011

Few cancers have a bleaker outlook than pancreatic cancer.

Oncology Community Facing Severe Drug Shortages

December 19th 2010

Hospitals, pharmacists, and physicians across the United States are reporting shortages of critical anticancer drugs, including carboplatin, cisplatin, dacarbazine, fludarabine, and cytarabine.

Therapeutic Vaccine Improves Survival in Patients with Pancreatic Cancer

August 16th 2010

New pancreatic cancer vaccine findings were presented at the 2007 Gastrointestinal Cancers Symposium, held January 19-21 in Orlando, FL.

FDA Grants Priority Review to Potential Liver Cancer Therapy

June 30th 2010

An oral therapy currently utilized in the treatment of advanced kidney cancer may be on the threshold of obtaining a major new indication.

Sorafenib (Nexavar) Becomes First and Only Approved Treatment of Hepatocellular Carcinoma in Europe

June 29th 2010

The European Commission has granted marketing authorization to sorafenib (Nexavar) for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer.

Sorafenib (Nexavar) Is Effective and Well Tolerated in Asian Patients with Advanced Hepatocellular Carcinoma

May 25th 2010

In an oral presentation, Ann-Lii Cheng, MD, PhD, National Taiwan University Hospital, Taipei, Taiwan, highlighted the results of a phase III study evaluating the efficacy and safety of sorafenib in patients from the Asia-Pacific region with advanced hepatocellular carcinoma (HCC).

Treatment with Gemcitabine (Gemzar) for Six Months After Complete Resection of Pancreatic Carcinoma Significantly Increases Disease-free Survival and Overall Survival Compared with Observation Alone

May 25th 2010

Although gemcitabine-based chemotherapy is standard in advanced pancreatic cancer, the role of adjuvant chemotherapy is still incompletely defined.

Colon Cancer Patients Not Getting Recommended Follow-Up Care

May 25th 2010

A new study shows that less than one half of older patients successfully treated for colorectal cancer receive the recommended screening schedule to detect any recurrence of cancer. The analysis indicates poor compliance with recommended monitoring of colorectal cancer survivors could affect survival.

Gastrointestinal Cancers: May 25, 2010

May 25th 2010

The 10th Annual Meeting of the World Congress on Gastrointestinal Cancer was held in Barcelona, Spain, in June. The Congress has grown into a key scientific program that covers malignancies affecting every component of the gastrointestinal tract and all facets of patient care, including screening, diagnosis, and management options for common and uncommon tumors.